Please login to the form below

Free Thinking: From promise to practice: immuno-oncology in action

This white paper explores the global outlook for new immunotherapy products, referencing key opinion leaders and payers to investigate how these products are faring both clinically and financially. 

Immuno-oncology therapies that harness the body's own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment.

Clinical trials of emerging products, both alone and in combination, have delivered impressive evidence of improvements in durability and endpoints such as progression-free survival, and even overall survival. R&D pipelines are stuffed with immuno-oncology prospects across a wide range of indications.

To date, only a few immuno-oncology products have actually reached the market though. Two of them target the anti-PD1/PD-L1 pathway where much of the interest in immuno-oncology is currently invested.

Download and read part 1 of the complimentary whitepaper at:

6th January 2016



Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Chester House
Fulham Green
81-83 Fulham High Street
United Kingdom

Latest content on this profile

How will COVID-19 affect uptake of vaccinations against other diseases?
Research Partnership
Living With Chronic Illness (Series one)
Research Partnership
Live webinar
China: How pharma can maximize success in this rapidly changing emerging market
Research Partnership
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma
Research Partnership
Migraine market snapshot
Research Partnership
Monitoring the impact of COVID-19 on the market access landscape
Research Partnership